density lipoprotein cholesterol (HDL-C), and triglycerides between mothers, fathers, sisters, and brothers of women with PCOS (referred to subsequently as "PCOS mothers," "PCOS fathers," etc.) and their controls were included. One of the following diagnostic criteria specified by the National Institutes of Health (4), the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine (5) , and/or the Androgen Excess Society (6) was required for diagnosis of PCOS in probands. Controls were reproductive-aged women without PCOS.
Data Extraction
Study characteristics (author, publication date, study design, and period), study population (sample size, age, body mass index [BMI] , study location, and ethnicity), selection criteria for first-degree relatives of PCOS probands and their controls, criteria used for PCOS, MetS, hypertension, and dyslipidemia diagnosis, and other parameters regarding systolic BP, diastolic BP, Total-C, LDL-C, HDL-C, and triglycerides were extracted from all included studies. When duplicate publications or secondary publications with overlapping patient populations were detected, the authors were contacted to collect non-overlapping data for inclusion in the meta-analysis. Two reviewers (B.Y. and B.O.Y.) extracted the data from all articles, with an inter-reviewer agreement of approximately 0.93. Any disagreement was resolved by consensus.
Metabolic syndrome was diagnosed according to the authors of the articles, the National Cholesterol Education Program Adult Treatment Panel III guidelines (2001), or American Heart Association criteria (13) . Controls were defined as age-comparable sex-matched individuals without a history of prior type 2 diabetes mellitus or impaired glucose tolerance and not taking any antihyperglycemic, antihypertensive medications or any medications for dyslipidemia.
Some of the studies by Dunaif, Legro, and colleagues (14) (15) (16) (17) used data from the National Health and Nutrition Examination Survey (NHANES) for control data. In the original articles, control subjects were of comparable age and BMI. Because it was unclear which control subjects were used for individual studies, and the NHANES data used were not available, the age range was selected as reported in each of the articles. For the PCOS sisters, comparable age for control women was defined as age between 18 and 47 years (14) . For the PCOS mothers, comparable age for control women was defined as age >40 years (17) .
For the PCOS brothers, comparable age for control men was defined as age between 16 and 48 years (18, 19) . For PCOS fathers, comparable age was defined as age >40 years (16) .
Outcome Measures
The primary endpoint was the risk ratio (RR) of MetS, hypertension, and dyslipidemia, and secondary endpoints involved systolic BP, diastolic BP, Total-C, LDL-C, HDL-C, and triglycerides in first-degree relatives compared with controls.
Risk of Bias Assessments
Each original study was assessed by two authors (B.Y. and P.V.) using the National Heart, Lung, and Blood Institute Quality Assessment Tool for Observational Cohort and Cross Sectional Studies. Disagreements were resolved by consulting a third author (B.A.).
Statistical Analysis
Dichotomous data from each of the eligible studies were combined for meta-analysis using the Mantel/Haenszel model. Results were expressed as RR with 95% confidence intervals (CIs). Continuous data from each of the eligible studies were combined for meta-analysis using the inverse variance method. Results were expressed as standardized mean difference (SMD) and 95% CI. Study-to-study variation was assessed by using the χ 2 statistic (the hypothesis tested was that the studies are all drawn from the same population, ie, from a population with the same effect size). A fixed effects model was used when there was no statistically significant heterogeneity between individual study results; otherwise a random effects model was applied. All results were combined for meta-analysis with RevMan software (version 5.2).
RESULTS

Characteristics of Included and Excluded studies
The electronic search returned 3,346 reports, as shown in Figure 1 . Fifty-eight studies were detected for assessment of full text by screening for title or abstract. Of these, 44 articles were excluded owing to not being published in English (20-22) (n = 3), inappropriate or no control group (23-27) (n = 5), overlapping patient population with previous publications (28, 29) (n = 2), and not including parents or siblings of women with PCOS (30-39) (n = 10). Likewise, studies using other diagnostic criteria or metabolic parameters (diagnosis according to interview or call) or studies not reporting required data for meta-analysis were also excluded (40-63) (n = 24). Finally, 14 studies were included in the meta-analysis (14) (15) (16) (17) (18) (19) (64) (65) (66) (67) (68) (69) (70) (71) . Ten studies by Dunaif, Legro, and colleagues (14) (15) (16) (17) (18) (19) (68) (69) (70) (71) included overlapping patient populations (confirmed by the authors), and individual patient data from these studies were included as a single study after exclusion of overlapping patients (data provided by Dunaif and colleagues).
The characteristics and demographic data of the included studies are summarized in Tables 1  and 2 . Author names, date of publication, study design and period, country of origin, and race are all presented for each included study in Table 1 . Studies by Yilmaz et al. (67) and Dunaif, Legro, and colleagues generated information for all PCOS mothers, fathers, sisters, and brothers (14-19, 68-71), whereas Davies et al. (65), Hunter et al. (66) , and Baillargeon and Carpentier (64) reported information about two (mother, father), two (father, brother), and one (brother) type of PCOS first-degree relative, respectively (Table 1) . Polycystic ovary syndrome probands and their controls were recruited from a hospital or clinic in a selected population. Moreover, comparability between the groups in terms of age and BMI was met in approximately half of the included studies (Table 2 ). In the combined Dunaif and Legro studies, mothers and fathers of women with PCOS were older than control subjects but did not differ in terms of BMI. There were no differences in age between PCOS sisters and controls, but PCOS sisters had a higher BMI. Polycystic ovary syndrome brothers were younger compared with controls, whereas BMI did not differ.
Most of the studies did not describe the criteria used for diagnosis of hypertension, dyslipidemia, and MetS, as shown in Supplemental Table 1 (available online) . Data regarding all primary and secondary endpoints were available only in 1 study (Dunaif and Legro studies combined [14] [15] [16] [17] [18] [19] [68] [69] [70] [71] ), whereas 2 studies (65, 66) reported about only two endpoints (Supplemental Table 2 ). Numbers of studies and patients included in metaanalyses for each parameter regarding mothers, fathers, sisters, and brothers of women with PCOS and their controls are shown in Supplemental Table 3 . Comparisons between PCOS fathers and controls are shown in Figure 2B , Supplemental was significantly higher in PCOS sisters than in similarly aged control women ( Fig. 2C and Supplemental Fig. 17) 
Meta-analysis PCOS mothers vs. controls-The
], P=.002) was significantly higher in sisters of women with PCOS than in control sisters (Supplemental Fig. 18 Figs. 19-21, respectively) . Conversely, diastolic BP, HDL-C, and prevalence of dyslipidemia did not differ between PCOS sisters and control sisters (Supplemental Figs. 22-24, respectively) . Comparisons between PCOS sisters and controls are shown in Figure 2C , Supplemental Table 6 Risk of bias assessment is presented in Supplemental Table 8 . Even though the participation rate was not reported in most of the articles, we think selection bias is very unlikely in the context. Only 2 of 14 studies recruited controls from somewhat different populations: Hunter et al. (66) from women with other gynecologic pathology than PCOS; and Taylor et al. (15) used data from a national cohort built for another purpose. However, regarding the research question, bias seems unlikely. Even though the majority of the studies did not report an a priori sample size calculation or CIs, given the numbers of participants and observed differences reaching significance in most studies, false-negative results seem unlikely. Unfortunately blinding is not mentioned in any article; however, laboratory results are objective outcome measures, which are unlikely to be affected by knowledge of study groups. Yet assessment bias cannot be reliably excluded for other outcomes. We think the overall quality of the evidence provided by these studies is good.
DISCUSSION
The present systematic review and meta-analysis of 14 comparative studies provides compelling evidence of increased prevalence of metabolic abnormalities in first-degree relatives of patients with PCOS compared with controls. The prevalence of MetS and dyslipidemia were increased in PCOS mothers; hypertension, MetS, and dyslipidemia in PCOS fathers; hypertension and MetS in PCOS sisters; and hypertension in PCOS brothers.
Polycystic ovary syndrome is not only a reproductive disorder but is also associated with metabolic dysfunction. Dyslipidemia is the most common metabolic abnormality in PCOS (12) , and PCOS is the leading cause of dyslipidemia among women of reproductive age (72) . Moreover, metabolic syndrome (73) (74) (75) , dyslipidemia (10, 76) , and cardiovascular disease (11) are also common problems in women with PCOS. Both the American College of Obstetricians and Gynecologists (9, 77) and the Androgen Excess and PCOS Society guidelines (6) recommend that PCOS patients should have a complete fasting lipid and lipoprotein evaluation as part of their cardiovascular risk assessment.
Familial aggregation of PCOS has been well established, consistent with a genetic susceptibility to the disorder; approximately 40% of premenopausal PCOS sisters have hyperandrogenemia, and other first-degree relatives have an increased risk of metabolic complications (14, 17-19, 42, 43, 45, 68-70) . Our results provide evidence of clustering of metabolic abnormalities in mothers, fathers, sisters, and brothers of women with PCOS: the prevalence of MetS (mothers, fathers, and sisters), hypertension (fathers, sisters, and brothers), and dyslipidemia (mothers and fathers) was found to be significantly increased. Moreover, meta-analysis of surrogate markers regarding these metabolic features shows the familial aggregation in PCOS relatives when compared with controls: systolic BP (mothers, sisters, and brothers), Total-C (mothers and sisters), LDL-C (mothers and sisters), and triglycerides (mothers and sisters) were significantly higher.
Metabolic syndrome is a progressive phenotype characterized by insulin resistance, abdominal obesity, hypertension, dyslipidemia, and type 2 diabetes, playing an important role in cardiovascular morbidity and mortality. There is growing evidence that in addition to environmental and behavioral factors, multiple genetic factors play an important role in the etiopathogenesis of MetS, dyslipidemia, and hypertension (78) (79) (80) . Thus, increased prevalence of these diseases in first-degree relatives of women with PCOS is not surprising.
There are several limitations of this systematic review and meta-analysis. Because we searched only PubMed and included studies published in English, there may have been a publication bias. Nevertheless, there were only three non-English studies excluded, and cross-checking the references of all full-text articles prevented missing any relevant information.
Moreover, most studies used gynecology or endocrinology clinic samples as the source of both PCOS and control subjects as a selected population, which may cause bias because these patients are expected to have higher risk for MetS, hypertension, and dyslipidemia than would a general population. Furthermore, differences in diagnostic criteria for PCOS, race/ ethnicity, and BMI might cause inaccurate estimation of the prevalence of MetS, hypertension, and dyslipidemia in the present meta-analysis. Of note, PCOS mothers and fathers were significantly older than the control population, whereas PCOS brothers were younger. Because the prevalence of MetS increases with age (81), it is possible that the prevalence of MetS was overestimated for PCOS mothers and fathers. However, PCOS parents had BMI similar to that of controls. The younger age of PCOS brothers compared with controls could potentially explain for the lack of statistical significance for some outcomes compared with controls. It is noteworthy that MetS and dyslipidemia tended to be more prevalent in PCOS brothers, and they had a significantly higher prevalence of hypertension despite being younger than the controls.
The inclusion of de-duplicated patient data from several studies by Dunaif, Legro, and colleagues as a single study into the meta-analyses could also decrease precision of the estimates. We deemed it appropriate to combine the data from these studies, because the patients and families were recruited from the same populations over time, and the exposure of interest (i.e., being a first-degree relative of a PCOS patient) would not have varied across this period. Moreover, all the studies were consistent in their findings; that is, even though the differences were short of statistical significance for some outcomes measures, PCOS first-degree relatives had either significantly or nonsignificantly higher BP and lipid levels in all publications reporting these outcomes (14) (15) (16) (17) (18) (19) (68) (69) (70) (71) . Yet when data from several studies are combined into a single study for pooled analyses, the overall weight of these studies is less than what it would have been had these studies been included separately. Moreover, the pooled effect estimates become less precise (i.e., the CIs are wider). The possible implications of the imprecision caused by combining data from the Dunaif and Legro studies are most relevant for meta-analyses [1] in which their point estimates are in the opposite direction from other smaller studies included in the same analysis, or [2] when the CI just slightly crosses unity and the difference seems statistically nonsignificant. When we examined all the analyses in this regard, it is possible that the magnitude of associations between having a first-degree relative PCOS patient and prevalence of hypertension and dyslipidemia could have been somewhat underestimated in the present work. Importantly, it is possible, that the increased prevalence of hypertension and dyslipidemia in PCOS fathers could have reached statistical significance. Likewise, higher LDL-C levels in PCOS mothers, fathers, and brothers, higher systolic and diastolic BP levels in fathers and sisters, and higher Total-C and triglyceride levels in PCOS brothers could have reached statistical significance. Yet given the observed trends and results, we do not think the overall conclusions stated below would be different.
Methodologic quality was also assessed for all studies, and imprecise methods or methods absent for determining particularly MetS, hypertension, or dyslipidemia diagnosis (e.g., selfreport, physician diagnosis) were detected. All studies included in this meta-analysis were cross-sectional. However, the best study design to determine risk for an outcome needs to be a prospective or retrospective cohort study, because it allows the investigator to establish timing and directionality of the incidence of events (82) . Studies with longitudinal follow-up to capture clinical outcomes regarding not only the prevalence but also incidence of MetS, hypertension, or dyslipidemia are needed to resolve questions about metabolic complications in PCOS relatives.
In conclusion, this meta-analysis suggests that mothers, fathers, sisters, and brothers of women with PCOS have an increased risk of MetS, hypertension, and dyslipidemia when compared with parents and siblings of women without PCOS. Therefore, the diagnosis of PCOS should initiate a thorough review of not only the proband but also the father, brother(s), and particularly mother and sister(s), with respect to metabolic disturbances. However, we are limited by the small number of studies investigating each parameter of metabolic abnormalities. Therefore, longitudinal prospective studies with large sample sizes and well-defined controls from unselected populations are needed in first-degree relatives of women with PCOS.
FIGURE 1.
Flow chart of study selection for systematic review and meta-analysis. 
TABLE 2
Age, BMI, and number of patients in each study regarding PCOS first-degree relatives and their controls. 
